Otros idiomas Johnson & Johnson Sao Paulo

Acciones

JNJB34

BRJNJBBDR002

Mercado cerrado - Sao Paulo Otros sitios de cotización 22:05:00 27/06/2024			Varia. Cinco días.	Varia. 1 de enero.
53,34 ^BRL	+4,65 %		-1,35 %	+5,83 %

27/06	La FDA estadounidense rechaza aprobar el fármaco contra el cáncer "misil guiado" de Merck-Daiichi	RE
24/06	El Tribunal Supremo de EE.UU. da una oportunidad a las farmacéuticas para frustrar la demanda por financiación del terrorismo	RE

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	00:47
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	24/06
Johnson & Johnson completes acquisition of Proteologix, Inc.	24/06
Sector Update: Health Care Stocks Edge Up in Afternoon Trading	21/06
Johnson & Johnson : dossier déposé dans la maladie de Crohn	21/06
Johnson & Johnson : le rachat de Proteologix est bouclé	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson Completes Acquisition of Proteologix	21/06
Johnson & Johnson Completes Acquisition of Proteologix, Inc.	21/06
Health Authority Warns of Brain Risks From Pseudoephedrine Medications	21/06
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	21/06
Johnson & Johnson Files Application With US FDA Seeking Approval of Tremfya to Treat Crohn's Disease	20/06
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease	20/06
Johnson & Johnson Submits Application to U.S. FDA Seek Approval of TREMFYA®? for the Treatment of Moderate to Severe Active Crohn's Disease	20/06
More than 60 Law Firms Oppose J&J Prepack Bankruptcy Scheme	20/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

Joseph Wolk, Director Financiero de J&J: Fin de la patente de su medicamento estrella

23 de enero 2024 a las 18:30